MX2020002367A - Imidazoquinolinas sustituidas. - Google Patents

Imidazoquinolinas sustituidas.

Info

Publication number
MX2020002367A
MX2020002367A MX2020002367A MX2020002367A MX2020002367A MX 2020002367 A MX2020002367 A MX 2020002367A MX 2020002367 A MX2020002367 A MX 2020002367A MX 2020002367 A MX2020002367 A MX 2020002367A MX 2020002367 A MX2020002367 A MX 2020002367A
Authority
MX
Mexico
Prior art keywords
imidazoquinoline derivatives
substituted imidazoquinolines
imidazoquinolines
substituted
agonists
Prior art date
Application number
MX2020002367A
Other languages
English (en)
Inventor
Christophe Henry
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2020002367A publication Critical patent/MX2020002367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a derivados de imidazoquinolina y a composiciones farmacéuticas que contienen los derivados de imidazoquinolina. Los derivados de imidazoquinolina de la invención son útiles como agonistas de receptores de tipo toll, en particular agonistas de TLR7, y promueven la inducción de ciertas citoquinas.
MX2020002367A 2017-09-06 2018-08-31 Imidazoquinolinas sustituidas. MX2020002367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/072352 WO2019048036A1 (en) 2017-09-06 2017-09-06 SUBSTITUTED IMIDAZOQUINOLINES
PCT/EP2018/073470 WO2019048350A1 (en) 2017-09-06 2018-08-31 SUBSTITUTED IMIDAZOQUINOLINES

Publications (1)

Publication Number Publication Date
MX2020002367A true MX2020002367A (es) 2020-07-20

Family

ID=59914433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002367A MX2020002367A (es) 2017-09-06 2018-08-31 Imidazoquinolinas sustituidas.

Country Status (14)

Country Link
US (2) US11267813B2 (es)
EP (1) EP3679038B1 (es)
JP (1) JP7241738B2 (es)
KR (1) KR20200050963A (es)
CN (1) CN111094287A (es)
AU (1) AU2018327414B2 (es)
BR (1) BR112020004504A2 (es)
CA (1) CA3074166A1 (es)
IL (1) IL273002B2 (es)
MX (1) MX2020002367A (es)
RU (1) RU2768629C2 (es)
SG (1) SG11202001925WA (es)
WO (2) WO2019048036A1 (es)
ZA (2) ZA202001266B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019048036A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES
PT3679025T (pt) * 2017-09-06 2022-06-01 BioNTech SE Imidazoquinolinas substituídas como agonistas de tlr7
CU24679B1 (es) * 2019-03-07 2023-09-07 BioNTech SE Proceso para la preparación de una imidazoquinolina sustituida
BR112022008039A2 (pt) * 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
WO2023083439A1 (en) * 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS585623B2 (ja) 1976-07-12 1983-02-01 日本電信電話株式会社 ファクシミリ通信方式
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
AU2003223467B2 (en) 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8778963B2 (en) 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2005283085B2 (en) * 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007056112A2 (en) * 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
JP2010519309A (ja) * 2007-02-20 2010-06-03 ノバルティス アーゲー 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
DK2155743T3 (da) * 2007-05-08 2012-11-05 Astrazeneca Ab Imidazoquinoliner med immunmodulerende egenskaber
SI2276486T1 (sl) 2008-03-24 2014-01-31 4Sc Discovery Gmbh Novi substituirani imidazokinolini
EP2419429B1 (en) 2009-04-16 2014-03-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines as inhibitors of protein kinases
CN103012398B (zh) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
PT3679025T (pt) 2017-09-06 2022-06-01 BioNTech SE Imidazoquinolinas substituídas como agonistas de tlr7
WO2019048036A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES

Also Published As

Publication number Publication date
EP3679038A1 (en) 2020-07-15
KR20200050963A (ko) 2020-05-12
ZA202001266B (en) 2021-08-25
US20220227756A1 (en) 2022-07-21
WO2019048036A1 (en) 2019-03-14
BR112020004504A2 (pt) 2020-09-15
RU2020112229A3 (es) 2021-10-06
US20200317663A1 (en) 2020-10-08
CN111094287A (zh) 2020-05-01
JP2020532570A (ja) 2020-11-12
WO2019048350A1 (en) 2019-03-14
IL273002B1 (en) 2023-04-01
AU2018327414B2 (en) 2024-02-15
IL273002B2 (en) 2023-08-01
RU2768629C2 (ru) 2022-03-24
JP7241738B2 (ja) 2023-03-17
RU2020112229A (ru) 2021-10-06
US11267813B2 (en) 2022-03-08
EP3679038B1 (en) 2024-04-03
AU2018327414A1 (en) 2020-03-19
CA3074166A1 (en) 2019-03-14
SG11202001925WA (en) 2020-04-29
ZA202101322B (en) 2022-09-28
IL273002A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2020002367A (es) Imidazoquinolinas sustituidas.
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MX2018003491A (es) Represores de htt y usos de estos.
IL254714B (en) History of quinoline and pharmaceutical preparations containing them
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
TN2017000555A1 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
GEP20217239B (en) Pharmaceutical composition
MX2020002366A (es) Imidazoquinolinas sustituidas como agonistas de tlr7.
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
TN2015000411A1 (en) Ceftolozane antibiotic compositions
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
GEP20217240B (en) Pharmaceutical composition
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IN2013MU03641A (es)